QUOTES

On new ADVANCE analyses (presented IDF congress 2009)

"*Intensive glucose control with a gliclazide MR-based regimen was effective in lowering HbA_{1C}, irrespective of age, duration of diabetes, sex, body mass index, or HbA_{1C} at study entry, and also irrespective of initial glucose lowering treatment. In addition, the gliclazide MR-based regimen was well-tolerated with very low rates of severe hypoglycemia and no weight gain.*"

Sophia Zoungas - ADVANCE study investigator, the George Institute for International Health, Australia.

"New results from ADVANCE provide insights into factors predicting risks of complications and confirm the efficacy and safety of the intensive gliclazide MR-based glucose control regimen across a broad range of participant subgroups. They reinforce guideline recommendations that HbA1c be lowered below 7% and to levels as low as 6.5%."

Professor John Chalmers - ADVANCE Principal Investigator, the George Institute for International Health, Australia.

On ADVANCE-ON

"ADVANCE is a huge reservoir of valuable clinical information. For this reason, we plan to continue the follow-up of the ADVANCE patients and we believe that this new study—ADVANCE-ON— will play a pivotal role in defining future clinical management of the tens of millions of people with type 2 diabetes worldwide."

Professor John Chalmers - ADVANCE Principal Investigator, the George Institute for International Health, Australia.

"The evidence provided by the ADVANCE-ON study, representing a contemporary cohort of patients with long standing diabetes from around the world, will either confirm or refute the UKPDS post-trial findings in patients with new onset diabetes, and play a pivotal role in defining future clinical management for tens of millions of individuals with type 2 diabetes worldwide."

Sophia Zoungas - ADVANCE study investigator, the George Institute for International Health, Australia